Atara Biotherapeutics, Inc. - שולי רווח נקי ממכירות ATRA

Diversification of T-cell developments in oncology and autoimmunology reduces risks for Atara Biotherapeutics (ATRA). Relative net sales profit confirms this resilience, with the latest parameter standing at -368.60. The company is implementing accessible off-the-shelf solutions against the Epstein-Barr virus. High capacity utilization of its own biotech plant guarantees the uninterrupted execution of all clinical drug production programs.
atarabio.com (ATRA) - פילוחי מדדים ודוחות פיננסיים

Analyzing Atara Biotherapeutics (ATRA) through the lens of net sales profitability allows for an assessment of the business's real efficiency. This indicator captures the share of final income in revenue, neutralizing the time lag associated with quarterly reporting. The metric's trend reflects the sensitivity of profit to tax adjustments and operating expenses. For Atara Biotherapeutics (ATRA), chemical raw material shortages driven by geopolitics directly reduce this margin. This figure serves as an indicator of the resilience of drug development under sanctions.